Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Interpersonal Violence and Mental Health, Drug use, and Treatment Utilization among Patients with Co-Occurring Opioid use and Mental Health Disorders.

Author information

Affiliations

  • 1. Health Care Division, RAND, Santa Monica, CA, USA.
      Authors
    • Hindmarch G 1
    • Meredith LS 1
    • McCullough CM 1
    • Watkins KE 1
    (4 authors)
  • 2. RAND Corporation, Arlington, VA, USA.
      Authors
    • Griffin BA 2
    (1 author)

ORCIDs linked to this article

Chronic Stress (Thousand Oaks, Calif.), 01 Jan 2024, 8:24705470241279335
https://doi.org/10.1177/24705470241279335 PMID: 39246736 PMCID: PMC11378169

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

Interpersonal violence is a common type of trauma experienced by people with opioid use disorder (OUD), especially for people with co-occurring OUD and mental illness (COD). However, little is known about demographic and clinical characteristics of individuals with COD who have experienced an interpersonal violence traumatic event compared to those who have experienced a non-violent trauma, and how experiences of interpersonal violence are associated with treatment utilization. Data presented are from a randomized clinical trial testing collaborative care for COD in primary care. Of the 797 patients enrolled in the larger study, 733 (92%) were included in this analysis because they reported a traumatic event. In this sample, 301 (41%) participants experienced a traumatic event involving interpersonal violence. Participants who experienced interpersonal violence were more likely to be younger and female. Among the 301 people who experienced interpersonal violence, 30% experienced child sexual abuse, 23% experienced physical violence, 19% experienced domestic violence, and 28% experienced sexual assault. Those who experienced physical violence were significantly less likely to be female (28.6% vs 74.2% to 88.2% in other groups). Those who reported domestic violence had significantly fewer days of drug use (4.1 days vs 9.0 to 11.5 in the other groups) and lower opioid use severity scores (mean = 13.0 vs 16.6 to 19.5 in the other groups). Multivariable regression results examining the associations between interpersonal violence experiences on treatment utilization revealed no statistically significant differences. Rates of receipt were high for medication for opioid use disorder (∼80%) in this sample while rates of mental health counseling were around 35% and rates of receiving mental health medication around 48%. These findings make an important contribution to understanding the associations between patient characteristics and traumatic experiences, and receipt of treatment for OUD and mental health problems among a sample of patients with COD.

Clinical trial registration

clinicalTrials.gov ID: NCT04559893.

Free full text 

Logo of cssLink to Publisher's site
Chronic Stress (Thousand Oaks). 2024 Jan-Dec; 8: 24705470241279335.
Published online 2024 Sep 5. https://doi.org/10.1177/24705470241279335
PMCID: PMC11378169
PMID: 39246736

Interpersonal Violence and Mental Health, Drug use, and Treatment Utilization among Patients with Co-Occurring Opioid use and Mental Health Disorders

Grace Hindmarch,corresponding author1 Lisa S. Meredith,1 Colleen M. McCullough,1 Beth Ann Griffin,2 and Katherine E. Watkins1
Author information Article notes Copyright and License information Disclaimer

Abstract

Interpersonal violence is a common type of trauma experienced by people with opioid use disorder (OUD), especially for people with co-occurring OUD and mental illness (COD). However, little is known about demographic and clinical characteristics of individuals with COD who have experienced an interpersonal violence traumatic event compared to those who have experienced a non-violent trauma, and how experiences of interpersonal violence are associated with treatment utilization. Data presented are from a randomized clinical trial testing collaborative care for COD in primary care. Of the 797 patients enrolled in the larger study, 733 (92%) were included in this analysis because they reported a traumatic event. In this sample, 301 (41%) participants experienced a traumatic event involving interpersonal violence. Participants who experienced interpersonal violence were more likely to be younger and female. Among the 301 people who experienced interpersonal violence, 30% experienced child sexual abuse, 23% experienced physical violence, 19% experienced domestic violence, and 28% experienced sexual assault. Those who experienced physical violence were significantly less likely to be female (28.6% vs 74.2% to 88.2% in other groups). Those who reported domestic violence had significantly fewer days of drug use (4.1 days vs 9.0 to 11.5 in the other groups) and lower opioid use severity scores (mean = 13.0 vs 16.6 to 19.5 in the other groups). Multivariable regression results examining the associations between interpersonal violence experiences on treatment utilization revealed no statistically significant differences. Rates of receipt were high for medication for opioid use disorder (~80%) in this sample while rates of mental health counseling were around 35% and rates of receiving mental health medication around 48%. These findings make an important contribution to understanding the associations between patient characteristics and traumatic experiences, and receipt of treatment for OUD and mental health problems among a sample of patients with COD.

Clinical trial registration

clinicalTrials.gov ID: NCT04559893

Keywords: trauma, interpersonal violence, co-occurring disorders, opioid use disorder, depression, posttraumatic stress disorder

Introduction

An estimated 6.7 to 7.6 million adults 1 in the United States live with opioid use disorder (OUD). There were 80,411 reported opioid overdose deaths in 2021, 2 and rates of OUD and opioid related fatalities are rising. 3 Almost all people with OUD have experienced one or more traumatic events.4,5 One study shows that over 90% of people with OUD report a traumatic event in their lifetime. 6 Interpersonal violence, an important subset of traumatic events in which harm is intentionally inflicted on a person by another (in contrast to traumatic events without violence such as experiencing an overdose), can worsen or contribute to opioid use.7–10 Research shows that using opioids may be an attempt to cope with the overwhelming, painful emotions that result from such traumas. 7 More than half of people in treatment for OUD report using opioids to lessen their symptoms of anxiety and sadness.11,12 Interpersonal violence can lead to developing PTSD, and therefore, it is not surprising that OUD and PTSD commonly co-occur.3,6,13,14

The bi-directional relationship between interpersonal violence experiences and substance use disorders (SUD) is well established. 10 Exposure to interpersonal violence is associated with the development of SUDs 9 and individuals with SUD are at greater risk of experiencing these types of events.15–17 Sexual violence, 18 childhood sexual abuse,18–24 physical abuse, 7 and intimate partner violence 24 are all associated with opioid use and the development of OUD. Patients with co-occurring OUD and mental health problems are at particularly high risk of interpersonal violence, as mental illness may make individuals more vulnerable to such events. 25 One study found that 60% of patients with co-occurring disorders had a history of interpersonal violence, a higher rate than patients with a mental disorder or SUD alone. 16 Compared to patients with a mental disorder or SUD alone, patients with co-occurring disorders have more severe and persistent mental health and SUD,16,26 are more likely to have experienced homelessness and incarceration,16,27,28 are more difficult to treat for mental health and SUD,16,26,29 and face significant barriers to care (eg, limited service availability/provision, poor disorder identification, insufficient provider training, racial/ethnic health disparities, and restricted insurance). 28

Despite the known association between OUD and interpersonal violence, there is little research describing the demographic and clinical characteristics of individuals with co-occurring disorders who have experienced interpersonal violence compared to non-violent traumatic events, and how these experiences are associated with mental health and OUD treatment utilization. Avoidant coping among those who experience interpersonal violence may decrease treatment utilization 30 and interfere with PTSD recovery. 31 Furthermore, interpersonal violence is often inflicted by people that the survivor knows,32–34 which complicates care-seeking if that person is still in their lives. 35 Many studies focus on only one type of interpersonal violence at a time (eg, child sexual abuse) or analyze the association between interpersonal violence across all categories, without looking at sub-types. 24 This study fills a gap in the interpersonal violence literature by describing the characteristics of people with and without interpersonal violence experiences and the types of interpersonal violence, among those with COD. Furthermore, the study fills a gap in the literature by examining whether experiencing interpersonal violence is associated with medications for opioid use disorder (MOUD) and mental health treatment utilization among people with co-occurring OUD and mental illness.

For the current study, we analyze self-reported baseline data from a randomized clinical trial of collaborative care for co-occurring OUD and PTSD and/or depression. 3 Collaborative care is a service delivery intervention in which a care coordinator works with patients and their primary care teams to support access to quality behavioral health care. 3 Among participants who reported an index trauma, we first compare those with and without interpersonal violence, and then further characterize the subsample of those who reported interpersonal violence by describing the specific type of violence experienced. We examine if the groups differ by demographics, mental health severity, drug use, and prior treatment utilization of medications and therapy for mental health problems and OUD.

Our study aims to answer three exploratory questions: What are the differences between individuals who have experienced trauma with and without interpersonal violence; is interpersonal violence associated with differences in OUD and mental health treatment utilization; and among individuals who have experienced interpersonal violence, are there differences in participant characteristics and OUD and mental health treatment utilization by type of interpersonal violence?

Method

Participants and Procedures

Data are from Collaboration Leading to Addiction Treatment and Recovery from other Stresses (CLARO), a randomized clinical trial of the effectiveness of collaborative care for COD in 14 primary care clinics in New Mexico and 4 clinics in California across 4 health care systems. Clinics serve a primarily low-income population and the majority of patients in the study are Hispanic. All study procedures were approved by the RAND's Institutional Review Board. Eligibility criteria for CLARO included: being 18 years or older, receiving primary care at a participating clinic, probable OUD with co-occurring depression and/or PTSD, English or Spanish fluent, capacity to give informed consent, and providing informed consent. Patients who required immediate medical or psychiatric intervention were excluded. 3 Eligibility criteria for the current study were enrolling in CLARO, reporting the experience of an index traumatic event, and completing the PCL-5 36 assessment for PTSD.

Measures

Characterization of Traumatic Event

Patients who reported a history of trauma on a baseline survey were asked to identify an index traumatic event (if they experienced more than one trauma, assessors asked participants to select one event in which they had the worst experience). The first author classified traumatic events as trauma with or without interpersonal violence. Examples of non-violent events included losing a loved one to suicide and witnessing an overdose. Interpersonal violence events were those involving harm intentionally inflicted on the patient by another person. Next, the interpersonal violence events were classified into 4 categories: child sexual abuse, physical violence, domestic violence, and sexual assault. Child sexual abuse included events where a person reported experiencing sexual violence when they were under the age of 18. Physical violence included events where a person's body was intentionally harmed by a perpetrator (excluding intimate partners or family), including gunshots, stabbings, robbery/burglary, bullying, etc. Domestic violence included events where a person reported that an intimate partner or family member physically or emotionally abused them. Finally, sexual assault included events where a person reported experiencing sexual violence as an adult, and included experiences of rape, sex trafficking, and stalking/harassment. Two authors (GH & LM) classified events into the interpersonal violence categories to ensure coding consistency.

After categorizing traumatic events into experiences of interpersonal violence or not, we explored differences between the groups for five sets of variables: (1) demographics, (2) social determinants of health, (3) mental health, (4) drug use, and (5) treatment utilization.

Demographics

The five demographic measures were age (in years), sex (coded as a binary indicator for female vs male), race/ethnicity scored as three categories (white, non-Hispanic; Hispanic, all races; or non-Hispanic), education scored as three categories (less than high school, high school or equivalent, or some college or more), and marital status in three categories (never married; married or living with a partner; or widowed, divorced, or separated).

Social Determinants of Health

Housing status was assessed with a binary indicator for living in stable housing in the past 3 months. Criminal justice system involvement was measured with a binary indicator for presently awaiting charges, trial, or sentencing; or having been on probation, parole, or supervised release from prison in the past 12 months.

Mental Health

General mental health was measured using The Veterans RAND 12-item Health Survey (VR12) mental health component score, 37 which aggregates 12 items to create a total score ranging from 0-100, with a higher score indicating better psychological functioning. PTSD symptoms were measured with the 20-item Posttraumatic Stress Disorder Checklist 36 for DSM-V (PCL-5) anchored to the index traumatic event. We measured depression symptoms with the 9-item Patient Health Questionnaire (PHQ-9). 38 Both sets of items are rated on a 0-4 scale symptom frequency scale. Items are summed to create total scores ranging from 0-80 for PTSD and 0-36 for depression; higher scores indicate greater symptomatology. We also included a binary indicator of suicidal ideation in the past 30 days from the Columbia Suicide Severity Rating Scale. 39

Drug use

Alcohol use severity was measured with the 10-item AUDIT anchored to the past three months. 40 Opioid use severity was assessed with the PROMIS Substance Use Short Form for the past 30 days. 41 We measured overdose risk using items from the Opioid Overdose Risk Assessment. 42 We assessed drug use frequency by taking the maximum value of the number of days of reported use of heroin, cocaine/crack, methamphetamine/other stimulants, and/or tranquilizers/sedatives in the past 30 days using items from the National Survey of Drug Use and Health (NSDUH). 43

Treatment Utilization

We measured treatment utilization in the past 30 days with three binary indicators: (1) receipt of medications for opioid use disorders (MOUD), (2) receipt of medication for depression/PTSD, and (3) therapy or counseling for depression/PTSD.

Data Analysis

Data Cleaning and Imputation

Missingness in our baseline data is generally very low (less than 5%). In instances where responses were missing due to valid survey skip logic, we performed a series of logical imputations to impute zeros. For example, when cleaning up data on suicidal thoughts, participants who indicated not having suicidal thoughts were given an imputed score of “no” for the variable that captures intention to act on them. Composite measures with item level missingness were scored following the measure scoring guideline's algorithm. If guidance for handling missing items in a composite measure was not reported in the literature, we calculated a scaled sum following the approach reported by Rezvan et al 44 (e.g., participants who completed more than 50% of items of the PCL-5 have non-missing items summed and then scaled up based on the number of missing items). For all other missing items, we mean imputed values within treatment assignment groups and health care system.

Statistical Methods

We stored and managed all trial data in SAS 9.4 and conducted all analysis using STATA version 17.0. To reduce the probability of type I error with multiple testing, we performed a Benjamini-Hochberg 45 correction with a false discovery rate (Q) = 0.05 after all analyses to determine the statistical significance of individual comparisons. First, we explored differences in variables among those with and without interpersonal violence using t-tests for continuous variables and chi-square tests for categorical and binary variables, adjusting accordingly for multiple testing using Benjamini-Hochberg (Table 1). Next, within the subpopulation of participants who experienced interpersonal violence, we compared differences in variables by the type of interpersonal violence experienced (i.e., child sexual abuse, physical violence, domestic violence, and sexual assault) using one-way ANOVA for continuous variables and chi-square tests for categorical and binary variables. We used the Benjamini-Hochberg correction to account for multiple hypothesis testing (Table 2). Finally, we sought to understand whether treatment utilization of mental health and MOUD rates varied by group, over and above demographic characteristics. We ran adjusted multivariable logistic regression analyses with treatment utilization measures as the dependent variables. The adjusted regression models controlled for the listed set of demographic characteristics, mental health diagnosis (i.e., depression, PTSD, or both), and health system. We report recycled predicted means with 95% confidence intervals for experience of any violence (Figure 2) and by violence category (Figure 3).

Table 1.

Characteristics for patients with and without interpersonal violence experiences, N = 733.

Baseline characteristic, n (%) or Mean (SD)TotalNo IPV
IPV		 p
Demographics
Age (years)39.8 (11.5)41.2 (12.0)37.9 (10.5)<.001
Female403 (55.0)195 (45.2)208 (68.9)<.001
Race/Ethnicity 0.762
White, non-Hispanic172 (23.5)97 (22.5)75 (24.8)
Hispanic, all races500 (68.2)298 (69.1)202 (66.9)
Other/more than one race, non-Hispanic61 (8.3)36 (8.4)25 (8.3)
Education 0.376
Less than high school224 (30.6)124 (28.8)100 (33.1)
High school or equivalent205 (28.0)127 (29.5)78 (25.8)
Some college or more304 (41.5)180 (41.8)124 (41.1)
Marital Status 0.186
Never married267 (36.4)164 (38.1)103 (34.1)
Married/living with partner271 (37.0)163 (37.8)108 (35.8)
Widowed/divorced/separated195 (26.6)104 (24.1)91 (30.1)
Social Determinants of Health
Stable housing past 3 months639 (87.2)377 (87.5)262 (86.8)0.775
Criminal involvement in past 12 months115 (15.7)76 (17.6)39 (12.9)0.084
Mental Health
VR12 mental health component score (range: 0-100)32.9 (12.6)33.5 (12.9)32.1 (12.1)0.120
PTSD symptom score (range: 0-80)38.2 (16.9)37.0 (17.3)39.9 (16.0)0.023
Depressive symptom score (range: 0-24)13.8 (5.8)13.7 (6.0)14.0 (5.5)0.631
Suicidal ideation (past 30 days)230 (31.4)135 (31.3)95 (31.6)0.945
Suicidal behavior (past 3 months)23 (3.1)10 (2.3)13 (4.3)0.129
Drug Use, 30 days prior to baseline
Alcohol use severity (range: 0-46)5.2 (8.9)5.7 (9.3)4.4 (8.2)0.060
Opioid use severity (range: 0-35)16.9 (9.5)16.9 (9.4)16.8 (9.7)0.862
Opioid overdose risk behaviors13.5 (6.2)13.8 (6.4)13.2 (5.9)0.201
Days with any drug use9.5 (12.3)9.6 (12.5)9.3 (12.2)0.735
Treatment Utilization, 30 days prior to baseline
Medication for OUD596 (81.3)350 (81.2)246 (81.5)0.932
Counselling for MH260 (35.5)145 (33.6)115 (38.1)0.216
Prescription for MH355 (48.4)206 (47.8)149 (49.3)0.681

Abbreviations: IPV: interpersonal violence; OUD: opioid use disorder; MH: mental health.

Table 2.

Characteristics for patients with different types of interpersonal violence experiences, n = 301.

Baseline characteristic, n (%) or Mean (SD)Child sexual abusePhysical violenceDomestic violenceSexual assault p
Demographics
Age (years)38.2 (9.9)37.6 (11.6)36.2 (10.3)38.9 (10.2).497
Female66 (74.2)a20 (28.6)b46 (80.7)a75 (88.2)a,c<.001
Race/Ethnicity .806
White, non-Hispanic21 (23.6)14 (20.0)17 (29.8)23 (27.1)
Hispanic, all races61 (68.5)51 (72.9)36 (63.2)53 (62.4)
Other/more than one race, non-Hispanic7 (7.9)5 (7.1)4 (7.0)9 (10.6)
Education .089
Less than high school33 (37.1)27 (38.6)21 (36.8)19 (22.4)
High school or equivalent20 (22.5)21 (30.0)16 (28.1)20 (23.5)
Some college or more36 (40.4)22 (31.4)20 (35.1)46 (54.1)
Marital Status .157
Never married24 (27.0)34 (48.6)18 (31.6)27 (31.8)
Married/living with partner37 (41.6)18 (25.7)21 (36.8)32 (37.6)
Widowed/divorced/separated28 (31.5)18 (25.7)18 (31.6)26 (30.6)
Social Determinants of Health
Stable housing past 3 months76 (85.4)59 (84.3)54 (94.7)73 (85.9).286
Criminal involvement in past 12 months8 (9.0)19 (27.1)5 (8.8)7 (8.2).001
Mental Health
VR12 mental health component score (range: 0-100)32.5 (12.1)35.3 (12.5)31.1 (11.6)29.6 (11.6).029
PTSD symptom score (range: 0-80)38.4 (16.4)38.9 (16.0)41.1 (14.9)41.4 (16.6).564
Depressive symptom score (range: 0-24)14.1 (5.1)13.6 (5.5)13.9 (6.0)14.2 (5.7).898
Suicidal ideation (past 30 days)25 (28.1)21 (30.0)15 (26.3)34 (40.5).223
Suicidal behavior (past 3 months)7 (7.9)2 (2.9)2 (3.5)2 (2.4).266
Drug Use, 30 days prior to baseline
Alcohol use severity (range: 0-46)5.0 (8.8)4.4 (8.4)4.8 (8.6)3.7 (7.2).754
Opioid use severity (range: 0-35)17.2 (9.5)a19.5 (10.3)a13.0 (7.4)b16.6 (10.0)a.002
Opioid overdose risk behaviors12.7 (5.1)14.5 (7.2)11.4 (4.8)13.7 (5.9).018
Days with any drug use9.0 (11.9)a10.7 (12.7)a4.1 (8.4)b11.5 (13.2)a.002
Treatment Utilization, 30 days prior to baseline
Medication for OUD74 (83.1)53 (75.7)49 (86.0)69 (81.2).482
Counselling for MH29 (32.6)24 (34.3)27 (47.4)35 (41.2).262
Prescription for MH46 (51.7)33 (47.1)33 (57.9)37 (43.5).370

Abbreviations: IPV: interpersonal violence; OUD: opioid use disorder; MH: mental health.

An external file that holds a picture, illustration, etc. Object name is 10.1177_24705470241279335-fig2.jpg

Regression adjusted means and 95% confidence intervals for reported receipt of treatment in the past 30 days for patients with and without violence experiences. Note. IPV: Interpersonal violence; MOUD: Medications for opioid use disorder; MH: Mental health.

An external file that holds a picture, illustration, etc. Object name is 10.1177_24705470241279335-fig3.jpg

Recycled predictions and 95% confidence intervals for reported receipt of treatment in the past 30 days for patients by type of violence experiences. Note. IPV: Interpersonal violence; MOUD: Medications for opioid use disorder; MH: Mental health.

Results

Figure 1 provides an overview of the sample flow for this study. Of 797 patients enrolled in the larger CLARO study 733 (92%) were included in this analysis. We excluded 64 (8%) participants because they did not report experiencing an index traumatic event. Of the 733 participants in this study's sample, 301 (41%) experienced a traumatic event involving interpersonal violence and 431 (59%) experienced a traumatic event without interpersonal violence.

Comparing Individuals with Traumatic Events with Versus Without Interpersonal Violence

Table 1 shows the results comparing baseline characteristics for participants who experienced traumatic events with and without interpersonal violence. Participants who had experienced interpersonal violence were, on average, 3.3 years younger (p < .001) and more likely to be female (68.9% vs 45.2%, p < .001) compared with those who had not experienced interpersonal violence. After adjusting for multiple testing, there were no additional statistically significant differences in the remaining variables.

Comparing Participant Characteristics by Type of Interpersonal Violence

Of the 301 people who experienced a traumatic event with interpersonal violence, 89 (30%) experienced child sexual abuse, 70 (23%) experienced physical violence, 57 (19%) experienced domestic violence, and 85 (28%) experienced sexual assault (Figure 1). Table 2 compares the characteristics of participants who experienced different types of interpersonal violence. Of note, participants reporting physical violence as their index traumatic event were less likely to be female (28.6%, all pairwise p < .001) than the other groups where higher proportions of participants reporting childhood sexual abuse (74.2%), domestic violence (80.7%), and sexual assault (88.2%) were female. Those who reported domestic violence as their index traumatic event reported fewer days of drug use (mean = 4.1 days, all pairwise p < .008) compared to those reporting the other types of traumatic events: childhood sexual assault (mean = 9.0 days), physical violence (mean = 10.7 days), and sexual assault (mean = 11.5 days). Those with a domestic violence index event also reported lower opioid use severity scores (mean = 13.0, all pairwise p < .025) than those with a child sexual assault (mean = 17.2), physical violence (mean = 19.5), and sexual assault (mean = 16.6) index event. After adjusting for multiple testing, there were no additional statistically significant differences in the remaining variables.

Multivariable Logistic Regression Analysis of Treatment Utilization Variables

Adjusted multivariable regression results for examining the associations between interpersonal violence experiences on treatment utilization revealed no statistically significant differences (see Figure 2). As shown, the rates of receipt were generally high for MOUD (~80% in both groups) in this sample. In contrast, rates of mental health counseling were only around 35% and rates of receiving medication were around 48%. Adjusted multivariable logistic regression models examining the association between different types of interpersonal violence (with physical violence as the reference group) on treatment utilization similarly revealed no statistically significant differences between groups (see Figure 3). Again, rates of receipt for MOUD were consistently high across groups ranging from 79% to 86%. Receipt of mental health counseling ranged from 32%-47% in the groups and ranged from 40%-58% for mental health medication.

Discussion

This study compares demographic and clinical characteristics of individuals with COD who have experienced trauma with and without interpersonal violence and explores the association between interpersonal violence and mental health and OUD treatment utilization. Our findings indicate that among patients with COD, those who are younger and female are more likely to have experienced interpersonal violence. This is consistent with past research; for example, Santo, et al, showed that among people with OUD, sexual abuse is more prevalent among women than men. 46 In addition, a systematic review found that across 18 studies, the estimated prevalence of intimate partner violence perpetrated against women who use opioids is 36%-94% in the lifetime and 32%-75% in the past year, demonstrating the complex relationship between interpersonal violence and opioid use especially in women. 10

Although overall rates of interpersonal violence in our study are higher for women than men, one exception to this pattern is that those who experienced physical violence are more likely to be male. This is consistent with a recent study categorizing interpersonal violence events among young people in SUD treatment into physical abuse, sexual abuse, or emotional abuse that found that the prevalence of all types of interpersonal violence was higher for women except for physical violence, which was higher in men. 47

These patterns indicate that providers should consider gender when screening and developing treatment plans for patients with co-occurring substance use and mental health disorders. Williams, et al, found gender differences in the types of violence associated with misuse of prescription opioids: intimate partner violence for men, adverse childhood experiences (ACEs) for women, and the interaction between intimate partner violence and sexual assault for women. The authors also note that there may be additional gender differences, but the effects are confounded when controlling for multiple traumatic events of differing types. 24 Another important reason to consider gender in treatment plans is that men and women may differ in why they misuse opioids. In one study, women more frequently report misusing opioids to cope with interpersonal stress, whereas men report misusing opioids to cope with pain and to increase euphoria. 48

Another key finding from our study is that a majority of participants who report experiencing interpersonal violence (58%) report an index traumatic event that involves either childhood sexual abuse (30%) or sexual assault (28%). This is consistent with a well-established association between ACEs and OUD.18–24 One study reports that 80% of MOUD seeking patients with OUD report a history of childhood trauma, including sexual abuse; 49 another finds that people with OUD are significantly more likely to report childhood traumatic events than people with SUD involving cocaine or nicotine. 17 These findings are also consistent with associations between OUD and the reported experience of sexual assault.18,24,50,51 For example, a study of patients with OUD reported that nearly 66% of women and 11% of men had experienced sexual violence and that sexual violence was associated with more complex clinical and social needs in both genders. 52

Given these associations, increasing screening for ACEs and sexual assault would likely benefit patients presenting with OUD. Despite the strong association between ACEs and/or sexual assault and OUD, screening for history of sexual violence in medical settings is uncommon and ACEs assessments are not standard for patients presenting with OUD.7,53 Other research has found that patients in treatment for OUD are generally not aware of the relationship between ACEs and current SUD, and that learning about the impact of ACEs provides relief and the belief that they are “normal”. 54 Furthermore, Driscoll et al suggest that asking about trauma allows patients to learn about normal reactions to trauma and provides information to care teams to make referrals for mental health care. 7 A different study successfully demonstrated that screening for ACEs in MAT clinics is an effective trauma-informed intervention that increases behavioral health referrals. 55 These studies suggest that screening for ACEs and trauma can be feasible for people with OUD, helps the patient feel understood, builds compassion between people with OUD and trauma and their providers, and increases access to behavioral health care. Of course, asking about sexual trauma is a highly sensitive topic that should be approached with great care and training on trauma informed practices. 56

Although experts recommend integrating mental health and substance use treatment for individuals with co-occurring disorders, we found mental health treatment utilization was lower than MOUD utilization. Studies suggest that people with co-occurring PTSD and SUD may benefit from trauma-focused interventions to help lower the high rates of dropout from treatment among people with co-occurring PTSD and SUD 57 and increase buprenorphine retention. 58 Despite the potential benefit of receiving integrated care for people with COD, many individuals with PTSD who are receiving buprenorphine treatment do not receive concurrent PTSD treatment. 58 Given the high burden and prevalence of interpersonal violence among people with COD, at 41% in our sample, it is important to further study the impact of trauma-focused care as a part of OUD treatment.

There are limitations to this study. Data come from two states (14 clinics in New Mexico and 4 in California) and from patients who receive care in primary care clinics, the majority of whom are engaged with MOUD. Therefore, our findings may not reflect experiences of interpersonal violence among people with OUD across the country, particularly those who are not engaged with the health care system and/or on MOUD. The work is also exploratory and aims to describe the complexity of patients who have experienced interpersonal violence among those with COD and cannot make claims of causality nor fully explain how the nuanced relationship between interpersonal violence and COD functions. Similar to other existing studies, 24 it uses cross-sectional data and cannot establish temporality between measures of interpersonal violence and opioid use, which is important in understanding potential causality.

Despite limitations, these findings make an important contribution to understanding the associations between patient characteristics and interpersonal violence experiences and receipt of treatment for OUD and mental health problems among a sample of patients with COD. Future work will aim to better understand how interpersonal violence affects treatment of OUD and mental health conditions. Additional work will also examine causal associations between interpersonal violence, overdose and suicide attempts, and mental health and OUD treatment utilization using longitudinal data.

Our study is a start to exploring interpersonal violence among people with co-occurring disorders and aims to show the complexity of the lives of people experiencing these disorders. These findings highlight the importance of compassion and trauma-informed care in health care settings for this population. We would be remiss to not mention the incredible resilience of people who have experienced interpersonal violence and are experiencing OUD and mental health problems. Our goal in conducting this work is to raise awareness about the challenges faced by people with COD and call for improvements to health service delivery for this population.

Acknowledgements

The CLARO Study Group includes the PIs and Co-Investigators, staff (such as project directors and patient representatives), and key stakeholders. The authors appreciate the CLARO partnerships with First Choice Community Healthcare, the University of New Mexico Health System, Hidalgo Medical System, and Los Angeles County Department of Health. We thank the RAND Survey Research Group staff, including Kirsten Becker, M.S., and University of New Mexico staff for their assistance in screening, recruiting, interviewing, and translating materials for patient research participants. We thank Liisa Ecola, M.P.P. for her help with project management, Carolina Ibarra for manuscript preparation, and Tiffany Hruby for manuscript preparation and project administrative expertise. Finally, we thank Michael Schoenbaum, PhD, the study Science Officer from the National Institute of Mental Health.

Footnotes

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant to Drs. Watkins and Komaromy (Multiple PIs) from the National Institute of Mental Health/NIMH (Grant number U01MH121954).

ORCID iD: Grace Hindmarch https://orcid.org/0009-0001-0356-0404

References

1. Keyes KM, Rutherford C, Hamilton A et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052. [Europe PMC free article] [Abstract] [Google Scholar]
2. National Institute on Drug Abuse. Drug overdose death rates. 2023, June 30, 2023. Accessed December 22, 2023. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:~:text=More%20than%20106%2C000%20persons%20in,drugs%20from%201999%20to%202021
3. Meredith LS, Komaromy MS, Cefalu M et al. Design of CLARO (collaboration leading to addiction treatment and recovery from other stresses): A randomized trial of collaborative care for opioid use disorder and co-occurring depression and/or posttraumatic stress disorder. Contemp Clin Trials. 2021;104:106354. [Europe PMC free article] [Abstract] [Google Scholar]
4. Peirce JM, Burke CK, Stoller KB, Neufeld KJ, Brooner RK. Assessing traumatic event exposure: Comparing the traumatic life events questionnaire to the structured clinical interview for DSM-IV. Psychol Assess. 2009;21(2):210-218. [Europe PMC free article] [Abstract] [Google Scholar]
5. Schacht RL, Brooner RK, King VL, Kidorf MS, Peirce JM. Incentivizing attendance to prolonged exposure for PTSD with opioid use disorder patients: A randomized controlled trial. J Consult Clin Psychol. 2017;85(7):689-701. [Europe PMC free article] [Abstract] [Google Scholar]
6. Mills KL, Lynskey M, Teesson M, Ross J, Darke S. Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): Prevalence and correlates. Drug Alcohol Depend. 2005;77(3):243-249. [Abstract] [Google Scholar]
7. Driscoll Powers L, Cook PF, Weber M, Techau A, Sorrell T. Comorbidity of lifetime history of abuse and trauma with opioid use disorder: Implications for nursing assessment and care. J Am Psychiatr Nurses Assoc. 2024;30(1):149-159. [Abstract] [Google Scholar]
8. Goodrum NM, Bernard DL, Moreland AD. Interpersonal violence, PTSD, and substance use types among women receiving substance use treatment. J Dual Diagn. 2022;18(3):123-134. [Europe PMC free article] [Abstract] [Google Scholar]
9. Khoury L, Tang YL, Bradley B, Cubells JF, Ressler KJ. Substance use, childhood traumatic experience, and posttraumatic stress disorder in an urban civilian population. Depress Anxiety. 2010;27(12):1077-1086. [Europe PMC free article] [Abstract] [Google Scholar]
10. Stone R, Rothman EF. Opioid use and intimate partner violence: A systematic review. Curr Epidemiol Rep. 2019;6(2):215-230. [Google Scholar]
11. Cicero TJ, Ellis MS. Understanding the demand side of the prescription opioid epidemic: Does the initial source of opioids matter? Drug Alcohol Depend. 2017;173(Suppl. 1):S4-S10. [Abstract] [Google Scholar]
12. Garland EL, Hanley AW, Thomas EA, Knoll P, Ferraro J. Low dispositional mindfulness predicts self-medication of negative emotion with prescription opioids. J Addict Med. 2015;9(1):61-67. [Europe PMC free article] [Abstract] [Google Scholar]
13. Dore G, Mills K, Murray R, Teesson M, Farrugia P. Post-traumatic stress disorder, depression and suicidality in inpatients with substance use disorders. Drug Alcohol Rev. 2012;31(3):294-302. [Abstract] [Google Scholar]
14. Meier A, Lambert-Harris C, McGovern MP, Xie H, An M, McLeman B. Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity. Am J Drug Alcohol Abuse. 2014;40(4):304-311. [Europe PMC free article] [Abstract] [Google Scholar]
15. Au VYO, Marsh DC, Rosic T, Samaan Z, Thabane L, Worster A. Trauma and post-traumatic stress disorder in patients treated for opioid use disorder: Findings from a 12-month cohort study. BJPsych Open. 2021;7(4):e138. [Europe PMC free article] [Abstract] [Google Scholar]
16. de Waal MM, Dekker JJM, Goudriaan AE. Prevalence of victimization in patients with dual diagnosis. J Dual Diagn. 2017;13(2):119-123. [Abstract] [Google Scholar]
17. Lawson KM, Back SE, Hartwell KJ, Maria MM-S, Brady KT. A comparison of trauma profiles among individuals with prescription opioid, nicotine, or cocaine dependence. Am J Addict. 2013;22(2):127-131. [Europe PMC free article] [Abstract] [Google Scholar]
18. Austin AE, Short NA. Sexual violence, mental health, and prescription opioid use and misuse. Am J Prev Med. 2020;59(6):818-827. [Abstract] [Google Scholar]
19. Austin AE, Shanahan ME. Association of childhood abuse and neglect with prescription opioid misuse: Examination of mediation by adolescent depressive symptoms and pain. Child Youth Serv Rev. 2018;86:84-93. [Google Scholar]
20. Basile KC, Clayton HB, Rostad WL, Leemis RW. Sexual violence victimization of youth and health risk behaviors. Am J Prev Med. 2020;58(4):570-579. [Europe PMC free article] [Abstract] [Google Scholar]
21. Lei Y, Xi C, Li P et al. Association between childhood maltreatment and non-medical prescription opioid use among Chinese senior high school students: The moderating role of gender. J Affect Disord. 2018;235:421-427. [Abstract] [Google Scholar]
22. Quinn K, Boone L, Scheidell JD et al. The relationships of childhood trauma and adulthood prescription pain reliever misuse and injection drug use. Drug Alcohol Depend. 2016;169:190-198. [Europe PMC free article] [Abstract] [Google Scholar]
23. Santo Jr T, Campbell G, Gisev N, Degenhardt L. Exposure to childhood trauma increases risk of opioid use disorder among people prescribed opioids for chronic non-cancer pain. Drug Alcohol Depend. 2022;230:109199. [Abstract] [Google Scholar]
24. Williams JR, Girdler S, Williams W, Cromeens MG. The effects of co-occurring interpersonal trauma and gender on opioid use and misuse. J Interpers Violence. 2021;36(23-24):NP13185-NP13205. [Abstract] [Google Scholar]
25. Azimi AM, Daigle LE. Mental health and victimization: Does risky lifestyle matter? J Interpers Violence. 2021;36(1-2):103-131. [Abstract] [Google Scholar]
26. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730-737. [Abstract] [Google Scholar]
27. Drake RE, Osher FC, Wallach MA. Homelessness and dual diagnosis. Am Psychologist. 1991;46(11):1149-1158. [Abstract] [Google Scholar]
28. Priester MA, Browne T, Iachini A, Clone S, DeHart D, Seay KD. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: An integrative literature review. J Subst Abuse Treat. 2016;61:47-59. [Europe PMC free article] [Abstract] [Google Scholar]
29. Hunt GE, Siegfried N, Morley K, Brooke-Sumner C, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2019;12(12):CD001088. [Europe PMC free article] [Abstract] [Google Scholar]
30. Reisig MD, Holtfreter K, Turanovic JJ. Criminal victimization, depressive symptoms, and behavioral avoidance coping in late adulthood: The conditioning role of strong familial ties. J Adult Dev. 2018;25(1):13-24. [Google Scholar]
31. Pineles SL, Mostoufi SM, Ready CB, Street AE, Griffin MG, Resick PA. Trauma reactivity, avoidant coping, and PTSD symptoms: A moderating relationship? J Abnorm Psychol. 2011;120(1):240-246. [Europe PMC free article] [Abstract] [Google Scholar]
32. Basile KC, Smith SG. Sexual violence victimization of women: Prevalence, characteristics, and the role of public health and prevention. Am J Lifestyle Med. 2011;5(5):407-417. [Google Scholar]
33. Larsen M-L, Hilden M, Lidegaard Ø. Sexual assault: A descriptive study of 2500 female victims over a 10-year period. BJOG Int J Obstet Gynaecol. 2015;122(4):577-584. [Abstract] [Google Scholar]
34. Tarzia L, Thuraisingam S, Novy K, Valpied J, Quake R, Hegarty K. Exploring the relationships between sexual violence, mental health and perpetrator identity: A cross-sectional Australian primary care study. BMC Public Health. 2018;18(1):1410. [Europe PMC free article] [Abstract] [Google Scholar]
35. Wilson KS, Silberberg MR, Brown AJ, Yaggy SD. Health needs and barriers to healthcare of women who have experienced intimate partner violence. J Womens Health (Larchmt). 2007;16(10):1485-1498. [Abstract] [Google Scholar]
36. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): Development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489-498. [Abstract] [Google Scholar]
37. Selim AJ, Rogers W, Fleishman JA et al. et al. Updated U.S. Population standard for the veterans RAND 12-item health survey (VR-12). Qual Life Res. 2009;18(1):43-52. [Abstract] [Google Scholar]
38. Spitzer RL, Kroenke K, Williams JB, Patient Health Questionnaire Primary Care Study Group. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. JAMA. 1999;282(18):1737-1744. [Abstract] [Google Scholar]
39. Posner K, Brown GK, Stanley B et al. The Columbia–suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. [Europe PMC free article] [Abstract] [Google Scholar]
40. Babor TF, Higgins-Biddle JC, Robaina K. USAUDIT - The alcohol use disorders identification test, adapted for use in the united states: A guide for primary care practitioners. Substance Abuse and Mental Health Services Administration; 2016. https://www.dshs.wa.gov/sites/default/files/BHSIA/dbh/wasbirt/USAUDIT-Guide_2016.pdf
41. Pilkonis PA, Yu L, Dodds NE et al. Item banks for substance use from the patient-reported outcomes measurement information system (PROMIS®): Severity of use and positive appeal of use. Drug Alcohol Depend. 2015;156:184-192. [Europe PMC free article] [Abstract] [Google Scholar]
42. Bohnert AS, Bonar EE, Cunningham R et al. et al. A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug Alcohol Depend. 2016;163:40-47. [Abstract] [Google Scholar]
43. Center for Behavioral Health Statistics and Quality. 2019 National Survey on Drug Use and Health (NSDUH): CAI specifications for programming (English version). Substance Abuse and Mental Health Services Administration; 2018. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHmrbCAISpecs2019.pdf
44. Rezvan PH, Comulada WS, Fernandes MI, Belin TR. Assessing alternative imputation strategies for infrequently missing items on multi-item scales. Commun Stat Case Styd Data Anal Appl. 2022;8(4):682-713. [Europe PMC free article] [Abstract] [Google Scholar]
45. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Stati Methodol. 1995;57(1):289-300. [Google Scholar]
46. Santo Jr T, Campbell G, Gisev N et al. et al. Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2021;219:108459. [Europe PMC free article] [Abstract] [Google Scholar]
47. DiGuiseppi GT, Ring CR, Rice ER, Davis JP. Sex differences in poly-victimization among youth experiencing homelessness prior to substance use treatment. Child Abuse Negl. 2022;129:105670. [Europe PMC free article] [Abstract] [Google Scholar]
48. Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36(8):829-834. [Europe PMC free article] [Abstract] [Google Scholar]
49. Sansone RA, Whitecar P, Wiederman MW. The prevalence of childhood trauma among those seeking buprenorphine treatment. J Addict Dis. 2009;28(1):64-67. [Abstract] [Google Scholar]
50. Balousek S, Plane MB, Fleming M. Prevalence of interpersonal abuse in primary care patients prescribed opioids for chronic pain. J Gen Intern Med. 2007;22(9):1268-1273. [Europe PMC free article] [Abstract] [Google Scholar]
51. Beckman KL, Williams EC, Hebert PL et al. et al. Associations among military sexual trauma, opioid use disorder, and gender. Am J Prev Med. 2022;62(3):377-386. [Abstract] [Google Scholar]
52. Schäfer I, Gromus L, Atabaki A et al. et al. Are experiences of sexual violence related to special needs in patients with substance use disorders? A study in opioid-dependent patients. Addict Behav. 2014;39(12):1691-1694. [Abstract] [Google Scholar]
53. Leserman J. Sexual abuse history: Prevalence, health effects, mediators, and psychological treatment. Psychosom Med. 2005;67(6):906-915. [Abstract] [Google Scholar]
54. Chandler GE, Kalmakis KA, Murtha T. Screening adults with substance use disorder for adverse childhood experiences. J Addict Nurs. 2018;29(3):172-178. [Abstract] [Google Scholar]
55. Pykare JD, Knox LH. Outcomes of a quality improvement project: Screening for adverse childhood experiences in medication-assisted treatment. J Doctoral Nurs Pract. 2022;15(3):157-164. [Abstract] [Google Scholar]
56. DeMaria AL, Meier S, King H, Sidorowicz H, Seigfried-Spellar KC, Schwab-Reese LM. The role of community healthcare professionals in discussing sexual assault experiences during obstetrics and gynecological healthcare appointments. BMC Womens Health. 2023;23(1):263. [Europe PMC free article] [Abstract] [Google Scholar]
57. Roberts NP, Roberts PA, Jones N, Bisson JI. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: A systematic review and meta-analysis. Clin Psychol Rev. 2015;38:25-38. [Abstract] [Google Scholar]
58. Meshberg-Cohen S, Black AC, DeViva JC, Petrakis IL, Rosen MI. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder. Addict Behav. 2019;89:29-34. [Abstract] [Google Scholar]
Articles from Chronic Stress are provided here courtesy of SAGE Publications

Full text links 

Read article at publisher's site: https://doi.org/10.1177/24705470241279335

Citations & impact 

This article has not been cited yet.

Impact metrics

Alternative metrics

Altmetric item for https://www.altmetric.com/details/168428802
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/168428802

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

Clinical Trials

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.